Skip to main content
Clinical Trials/NCT02700555
NCT02700555
Terminated
Not Applicable

Surveillance of Metabolic Parameters in Patients Who Will Receive Chemotherapy After Surgical Resection of Colorectal Cancer: KBSMC Colon Cancer Cohort

Kangbuk Samsung Hospital1 site in 1 country23 target enrollmentFebruary 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Colorectal Cancer
Sponsor
Kangbuk Samsung Hospital
Enrollment
23
Locations
1
Primary Endpoint
Incidence of newly developed diabetes mellitus
Status
Terminated
Last Updated
3 years ago

Overview

Brief Summary

A prospective, single center, cohort study for surveillance of metabolic parameters in patients who will receive chemotherapy after surgical resection of colorectal cancer

Detailed Description

Primary objective - Incidence of newly developed diabetes mellitus in patients with colorectal cancer after post-operative chemotherapy Secondary objective - Pre-operative incidence of diabetes and characteristics of metabolic parameters of patients with colorectal cancer; Incidence of developed poorly controlled glucose level in diabetic patients with colorectal cancer after post-operative chemotherapy; 3-year recurrence-free survival according to status of diabetes and metabolic parameters; 5-year recurrence-free survival according to status of diabetes and metabolic parameters

Registry
clinicaltrials.gov
Start Date
February 2016
End Date
February 2020
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Kangbuk Samsung Hospital
Responsible Party
Principal Investigator
Principal Investigator

Dong-Hoe Koo

Assistant Professor

Kangbuk Samsung Hospital

Eligibility Criteria

Inclusion Criteria

  • Who will get surgical resection for colorectal cancer
  • Who has diagnosed with diabetes
  • Who met the criteria for testing of diabetes in asymptomatic adult individuals
  • Criteria for testing for diabetes in asymptomatic adult individuals
  • overweight (BMI\>25 kg/m2\*) and have additional risk factors (physical inactivity, first-degree relative with diabetes, high-risk race/ethnicity (e.g., African American, Latino, Native American, Asian American, Pacific Islander), women who delivered a baby weighing 0.9 lb or were diagnosed with GDM, hypertension (\>140/90 mmHg or on therapy for hypertension), HDL cholesterol level ,35 mg/dL (0.90 mmol/L) and/or a triglyceride level \>250 mg/dL (2.82 mmol/L), women with polycystic ovarian syndrome, HbA1C \>5.7%, IGT, or IFG on previous testing, other clinical conditions associated with insulin resistance (e.g., severe obesity, acanthosis nigricans), history of CVD)

Exclusion Criteria

  • Previously exposed to surgery or chemotherapy for colorectal cancer
  • Second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin or prior malignancy treated more than 5 years ago without recurrence
  • Presence of CNS metastasis
  • Not able or willing to give informed consent
  • Any patients judged by the investigator to be unfit to participate in the study

Outcomes

Primary Outcomes

Incidence of newly developed diabetes mellitus

Time Frame: up to 12 months

Incidence of newly developed diabetes mellitus in patients with colorectal cancer after post-operative chemotherapy

Secondary Outcomes

  • 3-year recurrence-free survival & 5-year recurrence-free survival(up to 36-60 months)
  • Pre-operative incidence of diabetes(up to 12 months)
  • Incidence of developed poorly controlled glucose level(up to 12 months)

Study Sites (1)

Loading locations...

Similar Trials